Survival benefit of early infant antiretroviral therapy is compromised when diagnosis is delayed.

dc.contributor.author	Wamalwa, D
dc.contributor.author	Benki-Nugent, S
dc.contributor.author	Langat, A
dc.contributor.author	Tapia, K
dc.contributor.author	Ngugi, Elizabeth N
dc.contributor.author	Slyker, JA
dc.contributor.author	Richardson, BA
dc.contributor.author	John-Stewart, GC
dc.date.accessioned	2013-07-04T06:53:35Z
dc.date.available	2013-07-04T06:53:35Z
dc.date.issued	2012-07
dc.identifier.citation	Pediatr Infect Dis J. 2012 Jul;31(7):729-31. doi: 10.1097/INF.0b013e3182587796	en
dc.identifier.uri	http://www.ncbi.nlm.nih.gov/pubmed/22544051
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/45047
dc.identifier.uri	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756892/
dc.description.abstract	Late presentation is common among African HIV-1-infected infants. Incidence and correlates of mortality were examined in 99 infants with HIV-1 diagnosis by 5 months of age. Twelve-month survival was 66.8% (95% confidence interval: 55.9-75.6%). World Health Organization stage 3 or 4, underweight, wasting, microcephaly, low hemoglobin, pneumonia and gastroenteritis predicted mortality. Early HIV-1 diagnosis with antiretroviral therapy before symptomatic disease is critical for infant survival.	en
dc.language.iso	en	en
dc.publisher	University of Nairobi	en
dc.title	Survival benefit of early infant antiretroviral therapy is compromised when diagnosis is delayed.	en
dc.type	Article	en
local.publisher	Department of Paediatrics	en